comparison of PAP smear and VIA for screening of cervical cancer
Not Applicable
- Conditions
- Health Condition 1: A64- Unspecified sexually transmitted disease
- Registration Number
- CTRI/2024/08/071936
- Lead Sponsor
- Dr Meena Chaudhari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
all the patient who are giving consent, icludesEarly marriage
Early pregnancy
Sexual activity at early age
Multi parity
Multiple sexual partner
Women with STI, leucorrhoea, abnormal vaginal bleeding
Exclusion Criteria
Unmarried patients.
Patients with bleeding P/V and active infection at the time of examination.
Pregnant women.
Patients with vaginal pessary
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sensitivity of VIA compare to Pap smear to identify cervical cancer in women. <br/ ><br>Timepoint: within month
- Secondary Outcome Measures
Name Time Method specificity of the VIA compare to PAP smear to identify cervical cancer.Timepoint: within month
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does CTRI/2024/08/071936 compare PAP smear and VIA in detecting high-risk HPV subtypes linked to cervical cancer?
What are the sensitivity/specificity differences between PAP smear and VIA in cervical cancer screening for A64-related populations?
Which molecular biomarkers correlate with VIA or PAP smear effectiveness in early cervical cancer detection?
What adverse outcomes are associated with VIA versus PAP smear in cervical cancer screening, particularly in A64 cases?
Are combination approaches of PAP smear, VIA, and HPV DNA testing improving cervical cancer screening accuracy in low-resource settings?